Korean Journal of Head & Neck Oncology (대한두경부종양학회지)

The Korean Society for Head and Neck Oncology (대한두경부종양학회)
권호 표지

The Study on Recurrence-Related Factors of the Thyroid Cancer Patients Received Postoperative Radioactive Iodine Ablation Therapy

술후 방사성 요오드 사멸요법을 받은 갑상선암 환자들의 재발 관련인자에 관한 연구

  • Koh Yang-Seok (Department of Surgery, Chonnam National University College of Medicine) ;
  • Yoon Jung-Han (Department of Surgery, Chonnam National University College of Medicine) ;
  • JaeGal Yong-Jong (Department of Surgery, Chonnam National University College of Medicine)
  • 고양석 (전남대학교 의과대학 외과학교실) ;
  • 윤정한 (전남대학교 의과대학 외과학교실) ;
  • 제갈영종 (전남대학교 의과대학 외과학교실)
  • Published : 2002.11.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background and Objective: Factors that are associated with the recurrence after radioactive iodine ablation therapy have not been identified yet. The aim of this study is to elucidate the factors that are related to the recurrence after thyroid surgery of the thyroid papillary cancer followed by radioactive iodine ablation therapy. Patients and Methods: Fifty four cases who had underwent thyroid cancer surgery and postoperative radioactive iodine ablation therapy were included in this study. Mean followup duration was 7 years. There were 41 women and 13 men. Data analysis was done retrospectively with medical record review. Chi-square test and Fisher's exact test was used for the statistical analysis. Results: Age over 40, capsular invasion, and loca invasion were the factors that were associated with the high rate of recurrence. But sex, size of the tumor, multiplicity and extent of the surgery were not related to the recurrence. Conclusion: Without the curative resection of the tumor, radioactive iodine ablation therapy cannot lower the recurrence rate. So aggressive resection of the thyroid papillary cancer is important.The more data accumulated and the longer the followup, the easier we can reveal the recurrence-related factors of postoperative radioactive ablation therapy.

Keywords

References

  1. Tubiana M, Schlumberger M, Rougier P, et al : Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer. 1985 ; 55 : 794-804 https://doi.org/10.1002/1097-0142(19850215)55:4<794::AID-CNCR2820550418>3.0.CO;2-Z
  2. Mazzaferri EL, Jhiang SM : Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. American J of Medicine. 1994 ; 97 : 418-428 https://doi.org/10.1016/0002-9343(94)90321-2
  3. Kebebew E, Clark OH : Differentiated thyroid cancer: complete rational approach. World J of Surg. 2000 ; 24 (8) : 942-951 https://doi.org/10.1007/s002680010165
  4. Spies WG, Wojtowica CH, Spies SM, et al : Value of posttherapy whole body ${131}I$ imaging in the evaluation of patients with thyroid carcinoma having undergone high dose ${131}I$ therapy. Clin Med. 1989 ; 14 : 793-800
  5. Baskin HJ : Effect of postoperative ${131}I$ treatment on thyroglobulin measurements in the follow-up of patients with thyroid cancer. Thyroid. 1994 ; 4 (3) : 239-242 https://doi.org/10.1089/thy.1994.4.239
  6. Coburn M, Teates D, Wanebo HJ : Recurrent thyroid cancer. Role of surgery versus radioactive iodine (${131}I$) Annals of Surg. 1994 ; 219 (6) : 587-593
  7. Ronga G, fiorentino A, Paserio E, et al : Can iodine ${131}I$ whole body scan be replaced by thyroiglobulin measurement in the post surgical follow-up differentiated thyroid carcinoma? J Nucl Med. 1990 ; 31 : 1766-1771
  8. Grant CS, Hay ID, Gough IR, et al : Local recurrence in papillary thyroid carcinoma: is extended of surgical resection important? Surgery. 1998 ; 104 : 954-962
  9. Fatourechi V, Ray ID : Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases : including comments on the role of serum thyroglobulin monitoring in tumor surveillance. Seminars in Nucl. Med. 2000 ; 30 (2) : 107-114
  10. Grunwald F, Menzel C, Fimmers R, Zamora PO, Biersack HJ : Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer. J of Nucl Med. 1996 ; 37 (12) : 1962-1964
  11. Degrossi OJ, Rozardos IB, Damilano S, et al : Serum thyroglobulin and whole body scanning as markers in the follow up of differentiated thyroid carcinomas. Medicina (B Aires). 1991 ; 51 : 291-295
  12. Cady B, Rossi R, Silverman M, et al : Further evidence of the validity of risk group definition in differentiated thyroid carcinoma Surgery. 1985 ; 98 : 1171-1178
  13. Parker SL, Tong T, Bolden S, Wingo PA : 1997 Cancer statistics, 1997 CA Cancer J Clin. 47 : 5-27
  14. Vikram B, Strong EW, Shah JP, et al : Intraoperative radiotherapy in patients with recurrent head and neck cancer. Am J of Surg. 1985 ; 150(4) : 485-487 https://doi.org/10.1016/0002-9610(85)90159-X
  15. Adams S, Baum RP : Intraoperative use of gamma-detecting probes to localize neuroendocrine tumors : Quarterly J of Nucl Med. 2000 ; 44(1) : 59-67
  16. Shimaoka K, Schoenfeld DA, Dewys WD, et al : A randomized trial ofdoxarubicin versus doxorubicin plus cisplatin in patients with advanced thyroid cancer. Cancer. 1985 ; 56 (9) : 2155-2160 https://doi.org/10.1002/1097-0142(19851101)56:9<2155::AID-CNCR2820560903>3.0.CO;2-E
  17. De Besi P, Busnardo B, Toso S, et al : Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. Journal of Endocrinological Investigation. 1991 ; 14(6) : 475-480 https://doi.org/10.1007/BF03346846
  18. Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F : DeGroot LJ. Serum thyroglobulin in the follow-up of patients with treated differentiate thyroid cancer. J of Clin Endo & Meta. 1994 ; 79(1) : 98-105 https://doi.org/10.1210/jc.79.1.98
  19. Scheumann GF, Gimm O, et al : Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg. 1994 ; 18 : 559